
Please try another search
Veru Inc. is a biopharmaceutical company. The Company is focused on developing medicines for the for the treatment of hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and other viral-related ARDS and for the management of breast and prostate cancers. The Company offers two FDA approved products within its sexual health program, including ENTADFI (tadalafil 5mg and finasteride 5mg capsule), for the treatment of benign prostatic hyperplasia and FC2 Female Condom (internal condom) (FC2), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. Its breast cancer drug pipeline has four clinical development programs for two drugs, such as enobosarm, an oral selective androgen receptor targeting agonist, and sabizabulin, an oral cytoskeleton disruptor. Its prostate cancer drug pipeline includes sabizabulin, VERU-100 and zuclomiphene citrate.
Name | Age | Since | Title |
---|---|---|---|
Mitchell S. Steiner | 61 | 2016 | Chairman, President & CEO |
Harry Fisch | 63 | 2016 | Vice Chairman & Chief Corporate Officer |
Mario Eisenberger | 73 | 2016 | Independent Director |
Xiaoqin Lu | 47 | 2021 | Independent Director |
Michael L. Rankowitz | 64 | 2018 | Independent Director |
Grace S. Hyun | 51 | 2020 | Independent Director |
Andrew Sproule Love | 79 | 2013 | Board Observer |
David D. Ho | 69 | 2023 | Chairman of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review